AI English summary of an SEC filing — figures as filed
Altria said it reported net earnings of $8,130 million for 2023, or $4.57 per basic and diluted share. Net revenues for the year were $24,483 million, and operating income was $11,547 million.
Key points
AI summaryAltria said it reported net earnings of $8,130 million for 2023, or $4.57 per basic and diluted share. Net revenues for the year were $24,483 million, and operating income was $11,547 million.
The company said it acquired NJOY Holdings on June 1, 2023, for a total consideration of about $2.9 billion. The total includes cash paid of about $2.75 billion, net of cash acquired, and a fair value of about $130 million for contingent payments of up to $500 million tied to FDA authorization.
The company said its net cash provided by operating activities for 2023 was $9,287 million. For the same year, it paid $6,779 million in dividends on common stock and repurchased shares for $1,000 million.
The company said it received about $1.8 billion, including interest, of the remaining payment for the IQOS System from Philip Morris International on July 2023. It said that as of December 31, 2023, it had a deferred pre-tax gain of $2.7 billion on the IQOS System, and that it expects to recognize this gain as income when it relinquishes its IQOS System rights on April 30, 2024.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Altria Net Earnings of $8,130 million in 2023, or $4.57 Per Share
Altria said it reported net earnings of $8,130 million for 2023, or $4.57 per basic and diluted share. Net revenues for the year were $24,483 million, and operating income was $11,547 million.
Source · Based on the filing body and exhibits
NJOY Acquisition Total Consideration About $2.9 billion
The company said it acquired NJOY Holdings on June 1, 2023, for a total consideration of about $2.9 billion. The total includes cash paid of about $2.75 billion, net of cash acquired, and a fair value of about $130 million for contingent payments of up to $500 million tied to FDA authorization.
Source · Based on the filing body and exhibits
Operating Cash Flow of $9,287 million in 2023
The company said its net cash provided by operating activities for 2023 was $9,287 million. For the same year, it paid $6,779 million in dividends on common stock and repurchased shares for $1,000 million.
Source · Based on the filing body and exhibits
IQOS Remaining Payment Received and $2.7 billion Deferred Gain
The company said it received about $1.8 billion, including interest, of the remaining payment for the IQOS System from Philip Morris International on July 2023. It said that as of December 31, 2023, it had a deferred pre-tax gain of $2.7 billion on the IQOS System, and that it expects to recognize this gain as income when it relinquishes its IQOS System rights on April 30, 2024.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…